Chris Takimoto, MD, PhD, FACP

Dr. Takimoto is the Chief Medical Officer of IGM Biosciences. Dr. Takimoto has 30 years of experience in cancer research and development, most recently as Senior Vice President, Oncology, Gilead Sciences. Prior to Gilead, Dr. Takimoto was Chief Medical Officer of Forty Seven, a biotechnology company formed out of Stanford University and acquired by Gilead […]

Sui Huang, MD, PhD

Dr. Huang is a professor at the Institute of Systems Biology (ISB), a Seattle-based biomedical research organization that leads the transformation of medicine enabled by genomics and big data. An overarching theme of the Huang Lab at ISB is the interface between normal cell development and cancer development, analyzed through the formal concepts of gene […]

David Parkinson, MD

Dr. Parkinson has served as President and Chief Executive Officer of ESSA Pharma Inc. since January 2016, and as a Director of the company since June 2015. Prior to joining ESSA he had been a Venture Partner at New Enterprise Associates, Inc. From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, […]

Eileen O’Reilly, MD

Dr. Eileen M. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering (MSK). She serves as the Section Head for Hepatopancreaticobiliary/ Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director for Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer and is an Attending Physician and Member at MSK and Professor […]

Patricia LoRusso, DO

Dr. Patricia LoRusso has been a practicing academic medical oncologist performing clinical/translational research in early phase clinical trials for 30 years, spending the first 25 years at Wayne State University/Karmanos Cancer Institute in Detroit, MI and transitioning to Yale University/Yale Cancer Center in 2014. Both institutions have NCI comprehensive designation status. She has had continuous […]